Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplati
Phase 3
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-jRCT2080222115
- Lead Sponsor
- Bristol-Myers Squibb K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 920
Inclusion Criteria
Non-small cell lung cancer (NSCLC) - squamous cell
Stage IV or recurrent NSCLC
Eastern Cooperative Oncology Group (ECOG) of 0 or 1
Exclusion Criteria
Brain Metastases
Autoimmune diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival (OS) in subjects who receive one dose of blinded therapy
- Secondary Outcome Measures
Name Time Method Overall Survival<br>Progression Free Survival